Radioactive iodine therapy: multiple faces of the same polyhedron

ABSTRACT The incidence of differentiated thyroid carcinoma (DTC) has increased in recent decades with early stage, low risk papillary thyroid cancer (PTC) being detected and diagnosed. As a result, the psychological, financial, and clinical ramifications of overdiagnosis and excessively aggressive t...

Full description

Bibliographic Details
Main Authors: Rosália do Prado Padovani, Sumedha V. Chablani, Robert Michael Tuttle
Format: Article
Language:English
Published: Brazilian Society of Endocrinology and Metabolism 2022-05-01
Series:Archives of Endocrinology and Metabolism
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972022000300393&tlng=en
_version_ 1811215221724807168
author Rosália do Prado Padovani
Sumedha V. Chablani
Robert Michael Tuttle
author_facet Rosália do Prado Padovani
Sumedha V. Chablani
Robert Michael Tuttle
author_sort Rosália do Prado Padovani
collection DOAJ
description ABSTRACT The incidence of differentiated thyroid carcinoma (DTC) has increased in recent decades with early stage, low risk papillary thyroid cancer (PTC) being detected and diagnosed. As a result, the psychological, financial, and clinical ramifications of overdiagnosis and excessively aggressive therapy are being increasingly recognized with many authorities calling for a re-evaluation of the traditional “one size fits all” management approaches. To address these critical issues, most thyroid cancer guidelines endorse a more risk adapted management strategy where the intensity of therapy and follow up is matched to the anticipated risk of recurrence and death from DTC for each patient. This “less is more” strategy provides for a minimalistic management approach for properly selected patients with low-risk DTC. This has re-kindled the long-standing debate regarding the routine use of radioactive iodine therapy (RIT) in DTC. Although recent guidelines have moved toward a more selective use of RIT, particular in patients with low-intermediate risk DTC, the proper selection of patients, the expected benefit, and the potential risks continue to be a source of ongoing controversy and debate. In this manuscript, we will review the wide range of clinical, imaging, medical team, and patient factors that must be considered when evaluating individual patients for RIT. Through a review of the current literature evaluating the potential benefits and risks of RIT, we will present a risk adapted approach to proper patient selection for RIT which emphasizes peri-operative risk stratification as the primary tool that clinicians should use to guide initial RIT management recommendations.
first_indexed 2024-04-12T06:18:59Z
format Article
id doaj.art-1def05c159744ad481b76d6a627b2f03
institution Directory Open Access Journal
issn 2359-4292
language English
last_indexed 2024-04-12T06:18:59Z
publishDate 2022-05-01
publisher Brazilian Society of Endocrinology and Metabolism
record_format Article
series Archives of Endocrinology and Metabolism
spelling doaj.art-1def05c159744ad481b76d6a627b2f032022-12-22T03:44:22ZengBrazilian Society of Endocrinology and MetabolismArchives of Endocrinology and Metabolism2359-42922022-05-0166339340610.20945/2359-3997000000461Radioactive iodine therapy: multiple faces of the same polyhedronRosália do Prado Padovanihttps://orcid.org/0000-0002-5497-6813Sumedha V. Chablanihttps://orcid.org/0000-0002-6695-9885Robert Michael Tuttlehttps://orcid.org/0000-0001-9899-9702ABSTRACT The incidence of differentiated thyroid carcinoma (DTC) has increased in recent decades with early stage, low risk papillary thyroid cancer (PTC) being detected and diagnosed. As a result, the psychological, financial, and clinical ramifications of overdiagnosis and excessively aggressive therapy are being increasingly recognized with many authorities calling for a re-evaluation of the traditional “one size fits all” management approaches. To address these critical issues, most thyroid cancer guidelines endorse a more risk adapted management strategy where the intensity of therapy and follow up is matched to the anticipated risk of recurrence and death from DTC for each patient. This “less is more” strategy provides for a minimalistic management approach for properly selected patients with low-risk DTC. This has re-kindled the long-standing debate regarding the routine use of radioactive iodine therapy (RIT) in DTC. Although recent guidelines have moved toward a more selective use of RIT, particular in patients with low-intermediate risk DTC, the proper selection of patients, the expected benefit, and the potential risks continue to be a source of ongoing controversy and debate. In this manuscript, we will review the wide range of clinical, imaging, medical team, and patient factors that must be considered when evaluating individual patients for RIT. Through a review of the current literature evaluating the potential benefits and risks of RIT, we will present a risk adapted approach to proper patient selection for RIT which emphasizes peri-operative risk stratification as the primary tool that clinicians should use to guide initial RIT management recommendations.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972022000300393&tlng=en
spellingShingle Rosália do Prado Padovani
Sumedha V. Chablani
Robert Michael Tuttle
Radioactive iodine therapy: multiple faces of the same polyhedron
Archives of Endocrinology and Metabolism
title Radioactive iodine therapy: multiple faces of the same polyhedron
title_full Radioactive iodine therapy: multiple faces of the same polyhedron
title_fullStr Radioactive iodine therapy: multiple faces of the same polyhedron
title_full_unstemmed Radioactive iodine therapy: multiple faces of the same polyhedron
title_short Radioactive iodine therapy: multiple faces of the same polyhedron
title_sort radioactive iodine therapy multiple faces of the same polyhedron
url http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972022000300393&tlng=en
work_keys_str_mv AT rosaliadopradopadovani radioactiveiodinetherapymultiplefacesofthesamepolyhedron
AT sumedhavchablani radioactiveiodinetherapymultiplefacesofthesamepolyhedron
AT robertmichaeltuttle radioactiveiodinetherapymultiplefacesofthesamepolyhedron